# STERIS plc (Ireland) (STE) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Medical Devices & Supplies. Price $231.35, market value $22.6 billion.

## Valuation
- **P/E (trailing): 28.3×** (5-yr avg 77.8×, 3-yr avg 40.6×). STERIS plc (Ireland) trades at 28.3× trailing earnings, well below its own five-year average of 77.8×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.67**. A PEG of 0.67 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.7×**. Each dollar of revenue is priced at 3.7×.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 14.7×**. Enterprise value is 14.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 4.1%** (5-yr avg 2.9%). Free cash flow equals 4.1% of the market value, above its five-year average of 2.9%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.5%**. The inverse of the P/E: 3.5% of the price is earned each year.

## Profitability
- **Gross margin: 44.4%**. STERIS plc (Ireland) keeps 44.4% of revenue after the direct cost of what it sells.
- **Operating margin: 18.9%**. 18.9% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 13.2%**. 13.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.9%**. 10.9% on shareholders' equity is solid.
- **Return on invested capital: 10.4%**. Return on all capital, debt included, is 10.4%.
- **Return on assets: 7.5%**. Each dollar of assets produces 7.5% of profit.

## Growth
- **Revenue growth (1 yr): 8.7%** (3-yr 9.4%/yr, 5-yr 13.8%/yr). Revenue grew 8.7% over the last year, against 13.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 27.9%** (3-yr 95.0%/yr, 5-yr 11.4%/yr). Earnings per share rose 27.9%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 35.0%/yr**. Free cash flow has compounded at 35.0% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.27**. Debt is 0.27 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.9×**. It would take 0.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.09** (quick 2.09). Current assets cover the next year's liabilities 2.09 times.
- **Altman Z-score: 5.79**. A Z-score of 5.79 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 9/9**. 9 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.19%** ($2.52 per share, trailing). STERIS plc (Ireland) yields 1.19%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 31%** (27% of free cash flow). 31% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 7.8%/yr** (1-yr 2.9%). The dividend has grown 7.8% a year over five years.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover STERIS plc (Ireland); the consensus is buy, with an average price target of $260.71 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -0.4%** (YTD -7.4%, 3-mo 0.3%). The shares are down 0.4% over twelve months including dividends.
- **From 52-week high: -14.1%** (18.6% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 0.40** (volatility 26%). Beta of 0.40 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STE · Page: https://foliofundamentals.com/stocks/ste

Not investment advice.